Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revascularization Should Not Be Endpoint For GP IIb/IIIa Inhibitors - Cmte.

Executive Summary

Urgent revascularization should not be included in composite endpoints for active controlled trials of new glycoprotein IIb/IIIa inhibitors, the Cardiovascular & Renal Drugs Advisory Committee agreed Oct. 14.

You may also be interested in...



Roche Is Discussing Lamifiban Submission Based On Troponin T Substudy

Roche is in discussions with regulatory authorities regarding an indication for its intravenous glycoprotein IIb/IIIa platelet aggregation inhibitor lamifiban, based on a prospective substudy of its pivotal Phase III trial.

Roche Is Discussing Lamifiban Submission Based On Troponin T Substudy

Roche is in discussions with regulatory authorities regarding an indication for its intravenous glycoprotein IIb/IIIa platelet aggregation inhibitor lamifiban, based on a prospective substudy of its pivotal Phase III trial.

GP IIb/IIIa Meta-Analysis Would Not Provide Suitable Active Control - Cmte.

A meta-analysis of approved GP IIb/IIIa inhibitors would not provide the best comparator arm for active-control trials of new drugs in the class, FDA's Cardiovascular & Renal Drugs Advisory Committee concluded Oct. 14.

Related Content

UsernamePublicRestriction

Register

PS035018

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel